Ryan Corbett
Analyst · Matt Summerville with D.A. Davidson. You may proceed
Thanks, Jim. Let’s start the discussion on Slide 6. This slide has a bit of a new look from prior quarters as we’ve added NdPr production volumes to the far right. As we’ve talked about in the past, our operating metrics will evolve as we shift from concentrate production and sales to NdPr oxide and metal production and sales. So over time, you will see certain upstream-related metrics fall away with updated metrics that represent our transition into separated products. I would also point out that you’ll see slightly different revenue headings in our P&L, which will also likely evolve over the coming quarters. What remains clear is the strong production volumes for Q3 on the far left of the slide at 10,766 metric tons, is very consistent with both Q2 and last year’s Q3 production. Sales volumes dropped about 1,499 metric tons compared to Q3 2022 and 1,094 metric tons sequentially. These declines were primarily due to the work in process line fills that Jim just mentioned and that we spoke about on prior calls. As a reminder, operating equipment at each Stage 2 process circuit as well as intermediate product storage needed to be filled with upstream product. We have now absorbed all of that concentrate into these circuits and transition to converting some of that upstream volume into separated products with 50 metric tons of NdPr oxide produced in the quarter. As we’ve also previewed, our transition to separated products comes with a change in the duration of our sales cycle with a slightly longer time to revenue for separated products than with our concentrate product. Early NdPr production is primarily being used to build inventory at our tolling partners to begin production of NdPr metal, which is further extending the time to revenue on the products produced this quarter. So this onetime transition is reducing our upstream sales and earnings without yet seeing the benefit of the midstream revenue and earnings, but we will quickly lap this impact as we move into 2024. On realized pricing highlighted in the middle of the page, you can see what the impact of lower NdPr market pricing had on our realized price of REO in concentrate, down just over 50% year-over-year. Sequentially, pricing declined about 8% to $5,718 per metric ton, a bit better than expectations as pricing stabilized and recovered late in the quarter. Lastly on this slide, our production cost per metric ton, excluding Stage 2 related costs, was essentially flat sequentially at about $1,600. Including Stage 2 related costs the cost per metric ton was a little over $2,000. As you would expect, we brought on a tremendous amount of incremental maintenance head count that mostly flows through the P&L and makes up a large portion of the $400 per metric ton that is Stage 2 related. With these changes to our operations and with the launch of scale separated product production, we will evolve our reporting of cost metrics going forward. Moving to Slide 7. On the far left, you can see the combined impact on revenues from the lower realized pricing and our lower sales volumes. In this instance, lower sales volumes of concentrate is counterintuitively positive for us as it means more internal consumption for NdPr production and eventually sales. As you can see, with most of the revenue decline driven by lower pricing, we see this flow through to our EBITDA in the quarter. Despite weak pricing and additional Stage 2 costs without corresponding sales, we reported a still solid EBITDA margin of 30% in the quarter. And moving to the far right, most of the change in adjusted EBITDA flowed through to our adjusted net income and therefore, our adjusted diluted EPS. Positively impacting the comparison was the significant interest income of roughly $14 million we are earning on our large cash balance. I would also point out that despite the challenging pricing environment, as Jim said Stage 1 continues to generate a modest amount of free cash flow as our cash from operations in the quarter was roughly $11 million, which includes significant investments in Stage 2 related costs and working capital, while our non-growth CapEx was only $4 million. I will talk about CapEx shortly, but to finish the thought on our P&L, we did see about $6 million of higher start-up costs compared to last year’s third quarter, understandably driven by the final push of commissioning of Stage 2 ahead of production of separated products within the quarter. Now that the majority of these assets are achieving commercial production, this line item should start to decline beginning in Q4 as it relates to Mountain Pass, but there will still be some costs related to the startup of our Fort Worth facility expected in that line item until commercial production there. In addition, depreciation, depletion and amortization increased to just under $17 million in the quarter, in line with our comments from our last earnings call. The year-over-year increase of nearly $15 million was driven by over $350 million of assets put into service over the last 12 months, most of which were related to Stage 2 and other investments at Mountain Pass. We do expect this will continue to climb as we put more assets into service in the coming quarters, including portions of the Texas magnetic facility. Lastly, on the P&L relative to last quarter, our full year expected GAAP tax rate is up a couple of percentage points, which you will see reflected as a slight increase in our year-to-date tax rate. This is partially driven by ongoing updates to our calculations of the 45x production tax credit and its impact to 2023 as well as our ongoing prioritization of minimizing cash taxes in the near and medium-term versus optimizing the GAAP rate. Similar to last quarter, small updates in the full year rate had an outsized impact on the current quarter’s book tax rate given the small pre-tax net loss. Turning to the balance sheet. Our cash balance remains very robust at nearly $1.1 billion of gross cash and just under $400 million on a net basis. Total CapEx in the quarter was about $59 million, while growth CapEx was $55 million. We now expect to spend up to $270 million in total CapEx this year, down from the $300 million we were expecting a quarter ago. Growth capital of approximately $250 million primarily consists of Stage 3, heavy rare earth separation and other investments in Mountain Pass. The reduction in our forecast is primarily due to the timing of payments as well as a strong focus on capital efficiency. With Stage 2 capital spending behind us, our expectations for the overall budget on our other major projects, heavy separations and Stage 3 remain generally intact with our prior views. An addition to upstream 60k, the Stage 1 expansion goal Jim mentioned, we continue to evaluate other exciting but smaller investment to Mountain Pass and additionally, are evaluating a high return on capital expansion of capacity at our Texas Stage 3 facility. We expect to provide further details on our 2024 capital plans on our Q4 call. But as always, we remain extremely focused on cash-on-cash returns and maintaining our fortress balance sheet. Taking a quick look at Q4 for you. Upstream and midstream production volumes will be affected by our typical 1-week plant turnaround. We may sound like a broken record when we talk about how this was our most thorough shutdown to date, but this is especially true this time around with the work performed on all of our Stage 1 and Stage 2 circuits and all supporting infrastructure. Note that we expect concentrate sales volumes will decline a fair amount quarter-over-quarter as we ramp our NdPr production and consume a greater portion of upstream production internally. But as we stated last quarter, much of our initial output of NdPr oxide is going to Southeast Asia to build inventory at our Meadow tolling partners. And therefore, we don’t expect material sales volumes from our NdPr production to begin until Q1. Concentrate realized pricing will likely be flat to slightly up sequentially, assuming recent NdPr pricing stability holds in the coming weeks. Importantly, as I stated in my opening, as we get through this transition period of shifting from concentrate sales to NdPr oxide and metal sales, and with line of sight to hitting our full production targets, we would expect to see results start to improve off of a likely trough from our transition impact in Q4 as we move through 2024. Needless to say, we expect the success of Michael’s team will begin to become more evident in the financials as we enter 2024. With that, I’ll turn it over to Michael to give you a more detailed update on those successes.